TrialLeukemia2003

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.

U J Scheuring et al.PubMed ↗Publisher ↗

No numbers read from the abstract.